Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $312000.0.

  • Taysha Gene Therapies' Amortizatization of Intangibles rose 505.05% to $312000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 588.24%. This contributed to the annual value of $1.2 million for FY2024, which is 296.11% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Amortizatization of Intangibles stood at $312000.0, which was up 505.05% from $308000.0 recorded in Q2 2025.
  • Taysha Gene Therapies' Amortizatization of Intangibles' 5-year high stood at $385000.0 during Q3 2022, with a 5-year trough of $274000.0 in Q4 2023.
  • Over the past 4 years, Taysha Gene Therapies' median Amortizatization of Intangibles value was $305000.0 (recorded in 2023), while the average stood at $311533.3.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first tumbled by 2077.92% in 2023, then skyrocketed by 985.4% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Amortizatization of Intangibles (Quarter) stood at $284000.0 in 2022, then dropped by 3.52% to $274000.0 in 2023, then rose by 9.85% to $301000.0 in 2024, then rose by 3.65% to $312000.0 in 2025.
  • Its Amortizatization of Intangibles was $312000.0 in Q3 2025, compared to $308000.0 in Q2 2025 and $339000.0 in Q1 2025.